WGS Stock Overview
A genomics company, provides personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
GeneDx Holdings Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$77.40 |
| 52 Week High | US$89.11 |
| 52 Week Low | US$2.47 |
| Beta | 2.1 |
| 1 Month Change | -1.66% |
| 3 Month Change | 92.87% |
| 1 Year Change | 2,497.32% |
| 3 Year Change | -49.78% |
| 5 Year Change | n/a |
| Change since IPO | -76.07% |
Recent News & Updates
Is GeneDx Holdings (NASDAQ:WGS) Using Too Much Debt?
Dec 16
GeneDx: Possibly Turning A Profit In 2025 (Rating Downgrade)
Dec 16GeneDx Rides Revenue Surge, But Valuation Risks Loom
Dec 09GeneDx Holdings Corp.'s (NASDAQ:WGS) P/S Is Still On The Mark Following 40% Share Price Bounce
Nov 23Recent updates
Is GeneDx Holdings (NASDAQ:WGS) Using Too Much Debt?
Dec 16GeneDx: Possibly Turning A Profit In 2025 (Rating Downgrade)
Dec 16GeneDx Rides Revenue Surge, But Valuation Risks Loom
Dec 09GeneDx Holdings Corp.'s (NASDAQ:WGS) P/S Is Still On The Mark Following 40% Share Price Bounce
Nov 23US$76.67 - That's What Analysts Think GeneDx Holdings Corp. (NASDAQ:WGS) Is Worth After These Results
Nov 01GeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium Term
Oct 30GeneDx Holdings: Stock To Keep Outperforming As Business Momentum Persists
Oct 21After Leaping 53% GeneDx Holdings Corp. (NASDAQ:WGS) Shares Are Not Flying Under The Radar
Oct 04Is GeneDx Holdings (NASDAQ:WGS) Using Debt Sensibly?
Aug 29GeneDx Holdings: Profits On The Horizon For AI Driven Health Platform
Aug 19Market Participants Recognise GeneDx Holdings Corp.'s (NASDAQ:WGS) Revenues Pushing Shares 28% Higher
Jul 27GeneDx Holdings Corp.'s (NASDAQ:WGS) 30% Jump Shows Its Popularity With Investors
Jun 12GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing
Jun 06Further Upside For GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Introduce Price Risks After 42% Bounce
Apr 24GeneDx Holdings Corp. (NASDAQ:WGS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.13
Feb 23The Market Lifts GeneDx Holdings Corp. (NASDAQ:WGS) Shares 107% But It Can Do More
Feb 22Improved Revenues Required Before GeneDx Holdings Corp. (NASDAQ:WGS) Stock's 56% Jump Looks Justified
Dec 20Analyst Forecasts Just Became More Bearish On GeneDx Holdings Corp. (NASDAQ:WGS)
Nov 02Not Many Are Piling Into GeneDx Holdings Corp. (NASDAQ:WGS) Stock Yet As It Plummets 49%
Nov 01Sema4 names Kevin Feeley as CFO
Aug 26Things Look Grim For Sema4 Holdings Corp. (NASDAQ:SMFR) After Today's Downgrade
Aug 20Sema4 Holdings Corp. (NASDAQ:SMFR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 19Sema4 Q2 2022 Earnings Preview
Aug 12Shareholder Returns
| WGS | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 2.6% | -4.1% | -2.4% |
| 1Y | 2,497.3% | -10.2% | 23.4% |
Return vs Industry: WGS exceeded the US Healthcare industry which returned -10.2% over the past year.
Return vs Market: WGS exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| WGS volatility | |
|---|---|
| WGS Average Weekly Movement | 16.6% |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: WGS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: WGS's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 1,000 | Katherine Stueland | www.genedx.com |
GeneDx Holdings Corp., a genomics company, provides personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery. The company accelerate the use of genomics and leverage clinical data to enable precision medicine as the standard of care. It utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process DNA-containing samples, analyzes information about patient-specific genetic variation, and generates test reports for clinicians and their patients.
GeneDx Holdings Corp. Fundamentals Summary
| WGS fundamental statistics | |
|---|---|
| Market cap | US$2.13b |
| Earnings (TTM) | -US$83.50m |
| Revenue (TTM) | US$267.23m |
8.0x
P/S Ratio-25.5x
P/E RatioIs WGS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WGS income statement (TTM) | |
|---|---|
| Revenue | US$267.23m |
| Cost of Revenue | US$104.59m |
| Gross Profit | US$162.63m |
| Other Expenses | US$246.13m |
| Earnings | -US$83.50m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.04 |
| Gross Margin | 60.86% |
| Net Profit Margin | -31.25% |
| Debt/Equity Ratio | 25.4% |
How did WGS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:39 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GeneDx Holdings Corp. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |
| Matthew Sykes | Goldman Sachs |